Arcus Biosciences Stock News

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced the first OS results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junct...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 60,300 shares of the Company's common...

Arcus Biosciences shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug, a rival to Merck.

Arcus Biosciences, Inc. (NYSE:RCUS ) Shareholder/Analyst Call October 6, 2025 10:00 AM EDT Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - Co-Founder, Chairman & CEO Richard Markus - Chief Medical Officer Jennifer Jarrett - Chief Operating Officer Juan Jaen - Co- Founder & President Conference Call Participants Rana McKay Yigal Nochomovitz - Citigr...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced new monotherapy data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC). At an inves...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 9,750 shares of the Company's common ...

Arcus Biosciences, Inc. (NYSE:RCUS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Jennifer Jarrett - Chief Operating Officer Richard Markus - Chief Medical Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 19,300 shares of the Company's comm...